A Cell Biologist’s View on APOL1: What We Know and What We Still Need to AddressOpen Access

Höffken, Verena; Braun, Daniela Anne; Pavenstädt, Hermann; Weide, Thomas

Review article (journal) | Peer reviewed

Abstract

APOL1 is the most recent member of the APOL gene family and is expressed exclusively in humans and a few higher primates. More than twenty years ago, it was discovered that APOL1 protects humans from infections by trypanosome subspecies that cause African sleeping sickness. Interestingly, by a co-evolutionary process between parasite and host, two APOL1 variants emerged, which, in addition to their trypanotoxic effects, are simulta- neously associated with a significantly increased risk for various different kidney diseases, which are now summarized as APOL1-mediated kidney diseases (AMKDs). The aim of this review is to highlight and formulate key aspects of APOL1’s cell biologic features, including questions and unaddressed aspects. This perspective may contribute to a deeper understanding of APOL1-associated cytotoxicity as well as AMKDs.

Details about the publication

JournalCells (Cells)
Volume14
Page range960null
StatusPublished
Release year2025 (24/06/2025)
Language in which the publication is writtenEnglish
DOI10.3390/cells14130960
KeywordsAPOL1; Apolipoprotein L1; APOL1-mediated kidney disease; AMKD; renal risk variants; nephrotoxicity; topology; ion pore

Authors from the University of Münster

Braun, Daniela Anne
Medical Clinic of Internal Medicine D (Nephrology and Rheumatology) (Med D)
Höffken, Verena
Medical Clinic of Internal Medicine D (Nephrology and Rheumatology) (Med D)
Pavenstädt, Hermann-Joseph
Medical Clinic of Internal Medicine D (Nephrology and Rheumatology) (Med D)
Weide, Thomas
Medical Clinic of Internal Medicine D (Nephrology and Rheumatology) (Med D)